A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.
Processes for the large-scale fractionation of human plasma using cold ethanol were initially developed by Edwin Cohn and his colleagues at Harvard to provide albumin as a treatment for shock in World War II. Procedures for further purification of gamma globulins and other proteins precipitating at lower concentrations of ethanol were then developed by Oncley et al. Gamma globulin rapidly replaced convalescent and animal sera for the prevention and treatment of infectious diseases such as measles, hepatitis, and polio, then came into widespread use as replacement therapy in the primary immune deficiencies, which emerged in the antibiotic era of the early 1950s. Although it took 40 years to develop preparations of gamma globulin that could be safely given intravenously, the eventual accomplishment of that goal has led to better treatment of antibody deficiency syndromes and also the wide use of high-dose intravenous immunoglobulin in autoimmune and inflammatory diseases. Those uses continue to expand even as monoclonal antibodies are being introduced for specific infectious diseases in high-risk populations.
Berger
Melvin
M
University Hospitals of Cleveland/Rainbow Babies and Children's Hospital, Department of Allergy, Immunology, and Rheumatology, 11100 Euclid Avenue, Cleveland, OH 44106, USA. mxb12@po.cwru.edu
D000911:Antibodies, Monoclonal / Q000266:history / Q000627:therapeutic use; D005060:Europe; D049673:History, 20th Century; D006801:Humans; D007136:Immunoglobulins / Q000266:history* / Q000627:therapeutic use; D007167:Immunotherapy / Q000266:history*; D014481:United States
D000911:Antibodies, Monoclonal; D007136:Immunoglobulins